Constrictive Pericarditis Associated with Coronavirus Disease 2019 (COVID-19): A Case Report

(E-pub Ahead of Print)

Author(s): SeyedAhmad SeyedAlinaghi, Maryam Ghadimi, Mehrnaz Asadi Gharabaghi, Fereshteh Ghiasvand*

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Article ID: e160921188928
Become EABM
Become Reviewer
Call for Editor


Since December 2019, there has been an increasing number of patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world. As of March 2020, the World Health Organization declared a global pandemic. To our best knowledge, this is the first report of a patient with SARS-CoV-2 infection presenting with constrictive pericarditis, possibly from the COVID infection. She was presented after a week of fever, persistent dry cough, and diarrhea. She received a single dose of hydroxychloroquine 400 mg, Oseltamivir 75 mg every 12 hours, lopinavir/ritonavir (Kaletra) 400/100 mg every 12 hours, and levofloxacin 750 mg daily. After 24 hours, she was immediately transferred to the Intensive Care Unit (ICU) because of dyspnea and progressive respiratory failure with a drop of the O2 saturation to 70%. After a week of progress, her respiratory condition deteriorated again. She was re-admitted to the ICU and she expired. She died due to isolated constrictive pericarditis, most probably caused by SARS-CoV-2.

Keywords: COVID-19, SARS-CoV-2, pneumonia, ARDS, pericarditis, cardiac tamponade

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e160921188928
Published on: 09 December, 2020
(E-pub Ahead of Print)
DOI: 10.2174/1871526520666201209145001
Price: $95

Article Metrics

PDF: 137